Exercise training does not improve myocardial diastolic tissue velocities in Type 2 diabetes by Loimaala, Antti et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
Cardiovascular Ultrasound
Open Access Research
Exercise training does not improve myocardial diastolic tissue 
velocities in Type 2 diabetes
Antti Loimaala*1, Kaj Groundstroem2, Marjo Rinne3, Arja Nenonen4, 
Heini Huhtala5 and Ilkka Vuori3
Address: 1Clinical Physiology and Nuclear Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland, 2Department of Medicine, Kymenlaakso 
Central Hospital, Kotka, Finland, 3UKK institute for Health Promotion Research, Tampere, Finland, 4Clinical Chemistry, Rheumatism Foundation 
Hospital, Heinola, Finland and 5School of Public Health, University of Tampere, Finland
Email: Antti Loimaala* - antti.loimaala@uta.fi; Kaj Groundstroem - kaj.groundstroem@uta.fi; Marjo Rinne - marjo.rinne@uta.fi; 
Arja Nenonen - arja.nenonen@reuma.fi; Heini Huhtala - heini.huhtala@uta.fi; Ilkka Vuori - ilkka.vuori@uta.fi
* Corresponding author    
Abstract
Background: Myocardial diastolic tissue velocities are reduced already in newly onset Type 2
diabetes mellitus (T2D). Poor disease control may lead to left ventricular (LV) systolic dysfunction
and heart failure. The aim of this study was to assess the effects of exercise training on myocardial
diastolic function in T2D patients without ischemic heart disease.
Methods: 48 men (52.3 ± 5.6 yrs) with T2D were randomized to supervised training four times a
week and standard therapy (E), or standard treatment alone (C) for 12 months. Glycated
hemoglobin (HbA1c), oxygen consumption (VO2max), and muscle strength (Sit-up) were measured.
Tissue Doppler Imaging (TDI) was used to determine the average maximal mitral annular early (Ea)
and late (Aa) diastolic as well as systolic (Sa) velocities, systolic strain (ε) and strain rate () from the
septum, and an estimation of left ventricular end diastolic pressure (E/Ea).
Results: Exercise capacity (VO2max, E 32.0 to 34.7 vs. C 32.6 to 31.5 ml/kg/min, p = .001), muscle
strength (E 12.7 to 18.3 times vs. C 14.6 to 14.7 times, p < .001), and HbA1c (E 8.2 to 7.5% vs. C
8.0 to 8.4%, p = .006) improved significantly in the exercise group compared to the controls
(ANOVA). Systolic blood pressure decreased in the E group (E 144 to 138 mmHg vs. C 146 to 144
mmHg, p = .04). Contrary to risk factor changes diastolic long axis relaxation did not improve
significantly, early diastolic velocity Ea from 8.1 to 7.9 cm/s for the E group vs. C 7.4 to 7.8 cm/s (p
= .85, ANOVA). Likewise, after 12 months the mitral annular systolic velocity, systolic strain and
strain rate, as well as E/Ea were unchanged.
Conclusion: Exercise training improves endurance and muscle fitness in T2D, resulting in better
glycemic control and reduced blood pressure. However, myocardial diastolic tissue velocities did
not change significantly. Our data suggest that a much longer exercise intervention may be needed
in order to reverse diastolic impairment in diabetics, if at all possible.
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Background
Type 2 diabetes mellitus (T2D) is a strong risk factor for
coronary heart disease and heart failure [1,2]. Patients
with poor glycemic control and hypertension have a
worse prognosis [3,4], which may at least partially
attribute to myocardial disease. It has been shown previ-
ously that although left ventricular (LV) ejection fraction
is normal, myocardial diastolic tissue velocities are
reduced already in the early phase of the disease, indicat-
ing incipient diabetic heart muscle disease [5]. When the
disease progresses also systolic dysfunction with wall
motion abnormalities occur [6,7]. More interestingly,
increased left ventricular filling pressure associates with
higher mortality after myocardial infarction in males,
which underlines the importance of effective treatment of
patients at risk [8]. However, to date there is no estab-
lished treatment to reverse diastolic dysfunction in T2D. It
has been shown that good glucose control decreases the
incidence of vascular complications [9], and lipid lower-
ing therapy reverses myocardial hypertrophy and
increases tissue velocities [10]. We thus hypothesized that
enhanced myocardial function after a physical exercise
program might also be observed. Tissue Doppler Imaging
(TDI) gives accurate velocity measures from individual
myocardial segments in various populations and disease
states, and is suited for monitoring sub-clinical changes
during interventions [11]. The aim of this study was to
investigate the effects of a randomized, controlled long-
term exercise-training program on major risk factors of
T2D, and as primary end-point measures on myocardial
early diastolic tissue velocities in middle-aged diabetic
patients without clinical macro- or micro vascular compli-
cations.
Methods
The study group consisted of 48 men with T2D diagnosed
less than three years earlier. Exclusion criteria were history
or ECG signs of myocardial infarction, conduction distur-
bance on ECG or history of arrhythmias, symptoms or
ECG signs of ischemia on maximal treadmill stress test,
wall motion abnormalities on resting echocardiogram,
significant valvular disease, any lung disease, history of
cardiomyopathy, rheumatoid arthritis or connective tis-
sue disease, insulin treatment, or any chronic disease
other than diabetes. Altogether 33 patients were treated
with oral hypoglycemic drugs and 20 patients were treated
for hypertension (ACE inhibitors 10, β blockers 2, Ca
antagonist 3, and ACE inhibitor combined with a diuretic
or Ca antagonist 5 patients).
After a detailed physical examination, the subjects were
randomized as follows: 1) control group (C), standard
treatment of T2D; 2) exercise group (E), standard treat-
ment of T2D plus jogging or walking twice a week at a
heart rate level corresponding to 65–75% of maximal oxy-
gen consumption (VO2max) on spiroergometry, and mus-
cle strength training twice a week at a predefined intensity.
The resistance training program was progressive, every ses-
sion included eight exercises for large muscle groups alter-
nating between trunk and upper and lower extremities.
Resistance for each exercise station was assessed by
repeated maximum (RM) tests. Three sets of 10–12 repe-
titions at 70–80% maximum voluntary contraction were
performed. Exercises in the training program were
changed every two months, and a new target heart rate
was set every six months based on changes in VO2max
measured during a follow-up treadmill test. Two sessions
out of four per week were supervised by a physiotherapist,
and heart rate and intensity controlled (Polar Smart Edge,
Polar Electro Oy, Kempele, Finland) and all sessions were
recorded in a diary. The minimum duration of a session
was 30 minutes at the target heart rate or intensity, and the
intervention lasted for 12 months. The investigation con-
forms with the principles outlined in the declaration of
Helsinki [12]. The study was approved by the Research
Ethics Committee of the Tampere University Hospital,
and all subjects signed an informed consent.
Measurements
All subjects performed a maximal treadmill exercise stress
test according to a standard protocol. Fasting (12 h) blood
samples were taken, and blood glucose was assessed by
the glucose dehydrogenase method (mmol/l), and gly-
cated hemoglobin (HbA1c, %) was assessed by the immu-
noturbidimetric method (Roche Ltd, Basel, Switzerland).
Training and vigorous exercise were not allowed for 24
hours before blood was drawn and 12-hour restriction
was applied for tea and caffeine products. Cobas Mira Plus
and Cobas Integra automatic analyzers were used for the
analyses. Total cholesterol was measured from serum and
lipoprotein fractions were determined using an enzymatic
method (CHOD-PAP, Boehringer Mannheim, Man-
nheim, Germany). High density lipoprotein (HDL) sub-
fractions were determined according to Kirstein and
Carlson [13]. Triglycerides were measured from frozen
samples by enzymatic hydrolysis (GPO-PAP, Boehringer
Mannheim, Mannheim, Germany). LDL cholesterol level
was calculated using Friedewald's formula [14].
Echocardiographic and tissue Doppler myocardial imaging 
measurements
2-D and M-mode echocardiographic techniques and pro-
jections were used in a standard fashion [15]. All images
were stored on magneto-optic discs using a commercially
available echocardiograph (VingMed System V, Horten,
Norway). Measurements were performed off-line. The
physician performing the measurements was unaware of
the clinical and study group data. Standard left ventricular
dimensions were taken from three consecutive cardiac
cycles. Color-coded TDI cine loops from the apical 4- andCardiovascular Ultrasound 2007, 5:32 http://www.cardiovascularultrasound.com/content/5/1/32
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2-chamber views with > 100 frames per second were used
for TDI measurements. Mean peak systolic (Sa, cm/s), and
early (Ea, cm/s) and late (Aa, cm/s) diastolic tissue veloc-
ities from the lateral mitral annulus were measured. Addi-
tionally, peak systolic strain (ε, %) and systolic strain rate
(, 1/s) were measured from the septum in order to assess
local myocardial deformation. As a non-invasive estimate
of the left ventricular end-diastolic pressure, the ratio of
mitral inflow early diastolic velocity to mitral annular
early diastolic velocity was determined (E/Ea). An average
of at least three measurements for the individual variables
was used in statistical analyses. Normal TDI values for
middle-aged men determined in our laboratory are: Sa 7.8
± 2.6 cm/s (p = .14 vs. T2D) and Ea 10.4 ± 2.6 cm/s (p =
.001 vs. T2D), Aa 4.8 ± 1.2 (p = .23 vs. T2D).
Statistical methods
Clinical characteristics of the intervention group and con-
trols are presented as means and standard deviations
(SD). Comparisons of clinical study variables between the
study groups were performed at baseline by analysis of
covariance with age as a covariate. Detection of a clinically
significant effect of exercise training on tissue velocities,
i.e. an increase of at least 20% in Ea velocity and a stand-
ard deviation of the estimate of 0.7 cm/s, with 80% power
and at the 5% significance level, would require 17 patients
in both study arms at study end. In order to compare the
systolic and diastolic velocities between the exercise and
the control group after the intervention, analysis of covar-
iance with baseline velocities and heart rate during TDI
measurements was used as a covariate, and the results are
presented as means, standard errors and 95% confidence
intervals for the differences (CI) (SPSS 12.0.1).
Results
Clinical and standard echocardiographic characteristics of
the subjects are presented in Table 1. Significant differ-
ences between the study groups were not observed at base-
line except that the LV internal diameter in diastole was
higher in the controls and the posterior wall thicker in the
E group. Marked changes in medication were not made
during the intervention, and use of sulfonylureas or met-
formin/insulin sensitizers was stable, two subjects in the
C group started insulin treatment. The left ventricular ejec-
tion fraction was similar before and after the intervention.
Table 2 summarizes the follow-up data on exercise per-
formance, blood pressure, mitral inflow velocities and
blood analyses. The E group met the requirements for
duration and intensity of both the endurance and muscle
strength training programs, average adherence to control-
led sessions was 1.5 times of two. VO2max improved in the
E group (Exercise +8.0%, Control -3.3%), and so did mus-
cle strength (Exercise +44%, Control 0%, Table 2). A sig-
nificant decrease in HbA1c  occurred in the E group,
whereas glucose control slightly worsened in the controls.
Plasma insulin was higher at entry and it decreased more
during the intervention in the E group, but the difference
was not statistically significant. SBP decreased on average
by 6 mmHg in the intervention group and by 2 mmHg in
the controls, the difference being significant (Table 2).
Plasma lipids at entry were quite similar in both groups
and marginally above current recommendations for dia-
betic patients. During the intervention, only minor
changes were observed, but the net differences in total and
HDL cholesterol were nearly significant (Table 2). Mitral
inflow velocities at the beginning and at study end were
not significantly different between the study groups.
Tissue Doppler measurements at baseline and at follow-
up are presented in Figures 1 to 3. The average maximal
mitral annular tissue velocities were slightly lower in the
C group and unaffected by anti-hypertensive medication
at baseline. During the 12 months only non-significant
changes in the mitral annular early and late diastolic
velocities were observed and they are within measurement
variability (Figure 1). Likewise, systolic velocity did not
improve in the E group. When myocardial deformation
was evaluated from the septum, changes in strain and
strain rate (Figures 2 and 3) were negligible, average max-
imal systolic strain improved slightly, being -24% at study
Table 1: Clinical and echocardiographic characteristics of    the study subjects at baseline. Values are means (SD).  
Group Control (n = 24) Exercise (n = 24) p value
Variable
Age (years) 52.8 (6.0) 52.8 (5.2) 0.98
Weight (kg) 94.1 (12.8) 90.2 (9.4) 0.22
SBP (mmHg) 146 (15) 144 (17) 0.60
DBP (mmHg) 89 (6) 88 (9) 0.77
EF (%) 68 (7) 71 (9) 0.32
IVSD (mm) 10 (2) 10 (2) 0.27
LVEDD (mm) 55 (6) 49 (7) 0.003
PWD (mm) 10 (2) 11 (1) 0.04
SBP = systolic blood pressure; DBP = diastolic blood pressure; EF = left ventricular ejection fraction; IVSD = inter-ventricular septal thickness in 
diastole; LVEDD = left ventricular internal diameter in diastole; PWD = posterior wall thickness in diastole.Cardiovascular Ultrasound 2007, 5:32 http://www.cardiovascularultrasound.com/content/5/1/32
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Table 2: Exercise and clinical data on the study groups. Values are means (SE).
Group Control (n = 24) Exercise (n = 24) p value
Variable
VO2max 0 mo 32.6 (1.1) 32.0 (1.1)
(ml/kg/min) 12 mo 31.5 (0.6) 34.7 (0.6)
Net diff 3.2
95% CI 1.4 to 5.0 0.001
Weight 0 mo 94.1 (2.2) 90.0 2.2)
(kg) 12 mo 92.4 (0.7) 91.4 (0.7)
Net diff -1.4
95% CI -2.8 to 0.1 0.072
Sit-up 0 mo 14.6 (9.6) 12.7 (7.3)
(times) 12 mo 14.7 (1.2) 18.3 (1.2)
Net diff 6.7
95% CI 4.3 to 9.0 < 0.001
HBA1c 0 mo 8.0 (1.3) 8.2 (2.1)
(%) 12 mo 8.4 (0.2) 7.5 (0.2)
Net diff -0.9
95% CI -1.6 to -0.3 0.006
Insulin 0 mo 13.6 (2.3) 16.7 (2.3)
(mmol/l) 12 mo 13.6 (1.3) 11.7 (1.3)
Net diff -1.9
95% CI -5.6 to 1.8 0.31
Cholesterol 0 mo 4.85 (.18) 4.63 (.18)
(mmol/l) 12 mo 4.89 (.11) 4.61 (.11)
Net diff -0.28
95% CI -.58 to 0.03 0.07
HDL 0 mo 1.13 (.05) 1.09 (.05)
(mmol/l) 12 mo 1.18 (.03) 1.12 (.03)
Net diff -0.06
95% CI -.13 to .02 0.14
LDL 0 mo 3.24 (.17) 3.15 (.17)
(mmol/l) 12 mo 3.17 (.10) 3.10 (.10)
Net diff -0.7
95% CI -.35 to .22 0.68
Triglycerides 0 mo 1.83 (.15) 1.70 (.15)
(mmol/l) 12 mo 1.80 (.13) 1.70 (.13)
Net diff -0.09
95% CI -.45 to 0.26 0.60
SBP 0 mo 146 (15) 144 (17)
(mmHg) 12 mo 144 (1.9) 138 (1.9)
Net diff -5.5
95% CI -10.8 to 0.2 0.041
E (m/s) 0 mo 0.69 (.03) 0.64 (.03)
12 mo 0.70 (.03) 0.71 (.03)
Net diff .01
95% CI -.07 to .09 0.77
A (m/s) 0 mo 0.66 (.03) 0.68 (.03)
12 mo 0.69 (.02) 0.71 (.02)
Net diff .02
95% CI -.04 to .09 0.46
VO2max = maximal oxygen consumption; 0 mo/12 mo = measurements at baseline and after 12 months of intervention; Net diff. = difference of 
change compared to the control group (analysis of covariance); 95% CI = 95% confidence interval for the net difference; Weight = body weight; Sit-
up = sit-up test, number of repetitions; HBA1c = glycated hemoglobin; Insulin = serum insulin; Cholesterol = total cholesterol; HDL = high-density 
cholesterol; LDL = low-density cholestrol; Triglycerides = blood triglyceride concentration; SBP = systolic blood pressure; E = mitral inflow early 
diastolic velocity; A = mitral inflow late diastolic velocity.Cardiovascular Ultrasound 2007, 5:32 http://www.cardiovascularultrasound.com/content/5/1/32
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end for the E group vs. -22% for the C group. However,
baseline values were normal. At study entry, mean E/Ea
was 8.4 in the E group and 9.4 in the C group (p = 0.29
adjusted for age, ANOVA), the values being near normal.
Eleven subjects in the C group and 10 in the E group had
a ratio above 8 but again, significant differences after the
intervention were not observed for E/Ea (E 9.0 vs. C 8.5, p
= 0.42).
Discussion
Lower myocardial tissue velocities and increased myocar-
dial reflectivity in diabetes indicate altered myocardial
structure and diastolic dysfunction is a dominant feature
[6,16]. To our knowledge, this is the first controlled study
examining the effects of a long-term, high intensity exer-
cise program on myocardial long-axis relaxation in T2D.
Patients with hypertrophic cardiomyopathy (HCMP)
without established myocardial hypertrophy have signifi-
cantly lower myocardial systolic tissue velocities com-
pared to normal subjects [17]. The lower early diastolic
resting velocities (25% on average compared to healthy
controls) in our population suggest a specific diabetic
heart muscle disease, predominantly diastolic dysfunc-
tion. It is characterized by several abnormalities such as
replacement fibrosis as well as decreased myocardial cap-
illary density, altered sarcoplasmic reticular calcium trans-
port, accumulation of fatty acid metabolites in myocytes,
and changes in autonomic innervation of the heart [2].
The primary aim of our study was to examine whether
multifactorial risk factor reduction can reverse myocardial
diastolic impairment or not. Although risk factors were
reduced significantly and the glucose control improved,
these changes did not translate into effect on measured
long axis tissue velocities or deformation. In fact, the
observed changes are in the range of method variability. It
seems that reversal of the functional changes in the
human diabetic heart requires a much longer exercise
intervention.
Patients with T2D have higher cardiovascular morbidity
compared to healthy subjects [18]. Diabetic heart disease
may develop and be a cause for excessive morbidity and
hospitalization for heart failure in long-lasting disease.
The study patients represent an average T2D population;
they were overweight and hypertensive with medication
(45%), and their glucose control was fair-to-poor. None
of the patients had a history or clinical evidence of micro
vascular complications or coronary artery disease on
Mean peak mitral annular long-axis tissue doppler velocities (cm/s) in the study groups at baseline and after 12 months Figure 1
Mean peak mitral annular long-axis tissue doppler velocities (cm/s) in the study groups at baseline and after 12 months. Values 
are means (SE).
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treadmill exercise stress test. It is well known that physical
exercise reduces mortality from cardiovascular causes in
several populations [19], e.g. by reducing blood pressure,
changing the lipid profile, and also perhaps by enhancing
the autonomic control of the heart [20]. Our patients
reached a significantly better glucose balance than the
controls, which is comparable to the results of intensive
medical treatment [9]. In addition, their systolic blood
pressure decreased and VO2max improved significantly, i.e.
the training was effective.
Sylvén et al. [21] reported that objective improvement in
myocardial systolic function and frequency of angina epi-
sodes can be obtained by gene therapy in inoperable
CAD. Along with new collateral vessel formation, myocar-
dial perfusion improved and this resulted in 25% higher
myocardial systolic tissue velocities during dobutamine
stress. If ischemia is the limiting factor of function, better
oxygen supply to the myocardium increases systolic tissue
velocities at stress. Our patients achieved higher oxygen
consumption after the intervention and thus their cardiac
Maximal systolic strain rate (1/s) from the septum Figure 3
Maximal systolic strain rate (1/s) from the septum.
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output at peak stress was improved. However, our patients
had lower resting long-axis diastolic velocities at baseline
compared to healthy subjects and no improvement
occurred. Diastolic velocities are dependent on the elastic
properties of the left ventricle that are greatly influenced
by increased collagen deposition and other aforemen-
tioned factors [2,16]. The endocardial myocytes suffer ear-
lier from sub-clinical ischemia than circular epicardial
fibers, which may result in lower systolic and diastolic
long-axis velocities. If true reversal of abnormalities had
occurred, an increase in diastolic velocities of at least 20%
would have been enough in our study. We have shown
recently that exercise training improves baroreflex sensi-
tivity in diabetics [22], which most likely is a result of
enhanced endothelial function. If so, the lower resting
diastolic tissue velocities in our patients are not due to
poor microcirculation and endocardial ischemia solely
[7], but to structural changes which are more resistant to
conventional therapy (or irreversible). It thus seems that
"the tissue velocity gap" of about 25% to normal early
diastolic tissue velocities needs a much longer or even
more intensive exercise program [5].
According to Patel et al., myocardial hypertrophy can be
reversed and myocardial function improved by simvasta-
tin in animals [10]. Concomitantly with the reduction of
the LV dimensions, the collagen volume fraction was
reduced and these resulted in significantly higher, 30% on
average, systolic and diastolic septal velocities in the
treated rats compared to the placebo group, and velocities
at the end of the study were near normal. More impor-
tantly, Weidemann et al. demonstrated in 16 patients with
Fabry disease that giving agalsidase β for twelve months
improves myocardial systolic function, both strain rate
(from 2.8/s to 3.7/s) and strain (from 34 % to 45%)
improved significantly and myocardial mass was reduced
[23]. In our patients, significant changes in LV dimensions
were not observed nor expected, although long-standing
physical training induces LV hypertrophy. Nevertheless,
improved metabolic control, decreased afterload, and
sympathetic nerve activity due to lower blood glucose lev-
els could have beneficial effects on myocardial diastolic
function. It seems that significant changes in major risk
factors by exercise do not translate into enhanced myocar-
dial relaxation during one-year follow-up unlike the struc-
tural changes produced by agressive medical therapy
[10,23]. Our results concur with those observed for a one-
month medical therapy in T2D patients [24]. These find-
ings suggest that the insignificant changes in tissue veloc-
ities and also in myocardial deformation are due to a too
short training period, or that the mechanisms activated by
medical therapy are different and more effective.
Although tissue velocities measured during stress might
be a more sensitive indicator of effect, our study design
was analogous to the Fabry study where resting velocities
were measured as well, and a clear treatment effect was
observed.
Clinical implications
Morbidity and costs for T2D increase rapidly worldwide
[25]. This is mainly due to changes in dietary habits and
lack of exercise, which results in an enormous increase in
diabetes-related complications. To date there is no known
treatment to reverse diabetic heart disease. This study
shows that, in order to repair the end-organ damage pro-
duced by decades of sedentary western life style, a much
longer non-pharmacological intervention (or aggressive
medical therapy) is needed to obtain improvement in
myocardial diastolic function in T2D. As demonstrated
recently, prevention of T2D conservatively is effective and
should be the first-line regimen to reduce the incidence of
diabetic complications [26]. In subjects with established
disease, good glycemic and risk factor control may slow
down the process of diastolic dysfunction, and postpone
the development of cardiac failure [27,28]. However, if
diastolic dysfunction is already present, the functional
"reserve" is smaller after myocardial infarction compared
to patients with normal hearts, and the patient outcome is
unfavorable.
A limitation of the study is that, although the change in
systolic blood pressure was statistically significant, it was
still quite moderate and smaller than by medical therapy
in general [29]. Food diaries were not used and consump-
tion of saturated fats was not known. However, dietary
advice is always given to T2D patients by GPs and the lipid
levels were moderate in both study groups, and more
importantly, this was an exercise intervention. Significant
weight reduction would have enhanced the blood pres-
sure decrease, which did not occur. Most obviously the
muscle mass replaced body fat mass. Despite these limita-
tions, the metabolic control was improved significantly
together with enhanced autonomous control of the heart.
However, further and much longer randomized studies
are needed to clarify the effect of physical exercise on myo-
cardial function in diabetes.
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